Circulating tumor DNA as a biomarker in early phase clinical trials
Cancer Cell · 2026-02 · 44 (2) · 240-247
DOI: 10.1016/j.ccell.2025.11.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-02. Verfasst von Harold N Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AstraZeneca, Daiichi-Sankyo.
Abstract (Originalsprache)
The clinical development of novel cancer therapeutics is rapidly evolving with the integration of molecular biomarkers to advance precision medicine. Circulating tumor DNA (ctDNA) represents a versatile tool to detect targetable alterations, predict therapeutic response, monitor tumor evolution, and inform pharmacokinetic and pharmacodynamic effects. This could accelerate early phase drug development and deepen our understanding of biological drivers of response and resistance. Herein, we highlight current applications and future opportunities for ctDNA as a multi-utility biomarker in early phase clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Foundation Medicine Inc., Boston, MA, USA.
- University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tyap@mdanderson.org.
Förderung
- AstraZeneca
- Daiichi-Sankyo
Zitieren
APA
Tan, H. N., Elliott, M. J., Silverman, I. M., Siu, L. L., & Yap, T. A. (2026). Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell, 44(2), 240-247. https://doi.org/10.1016/j.ccell.2025.11.011
Vancouver
Tan HN, Elliott MJ, Silverman IM, Siu LL, Yap TA. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell. 2026;44(2):240-247. doi:10.1016/j.ccell.2025.11.011
BibTeX
@article{Tan2026,
author = {Tan, Harold N and Elliott, Mitchell J and Silverman, Ian M and Siu, Lillian L and Yap, Timothy A},
title = {Circulating tumor DNA as a biomarker in early phase clinical trials},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {2},
pages = {240--247},
doi = {10.1016/j.ccell.2025.11.011}
}
EUVIMED